Demystifying the CTD: A Biotech Roadmap

For many biotech startups, the Common Technical Document (CTD) feels like a distant NDA concern. In reality, structuring your IND in CTD format from day one can be a game-changer—reducing rework, improving consistency, and, in documented cases, saving three to six months in approval timelines [8].

What is the CTD?

The CTD is a globally harmonized dossier format developed by the International Council for Harmonisation (ICH) for regulatory submissions [1], organized into five modules:

1. Module 1 – Regional administrative information (varies by country)
2. Module 2 – Summary documents (clinical, nonclinical, quality)
3. Module 3 – Quality (CMC)
4. Module 4 – Nonclinical study reports
5. Module 5 – Clinical study reports

Although FDA INDs are not required to be in strict CTD format [3][4], aligning IND content to the CTD framework from the outset ensures a smoother transition to NDA (FDA) or MAA (EMA) and reduces the need for major reorganization later [2][5][6].

IND, NDA, and IMPD – What’s the Difference?

• IND (Investigational New Drug application): U.S. submission to begin clinical trials; often narrative-driven but can follow CTD format [3][4].
• NDA (New Drug Application): U.S. marketing approval submission; must follow CTD Modules 1–5 [2][5].
• IMPD (Investigational Medicinal Product Dossier): EU clinical trial application; already in CTD format [7].

Key point: If you aim for both U.S. and EU markets, CTD-aligned IND content means less reformatting and faster parallel submissions [7].

Evidence for Time Savings

A 2019 DIA panel reported that companies who adopted CTD formatting at IND stage shaved an average of 3–6 months from MAA/NDA preparation [8], particularly when pursuing simultaneous FDA/EMA submissions. Publicly available case studies from oncology programs show early CTD alignment reduced reviewer questions and prevented costly resubmissions [8].

Case Study

A mid-size oncology biotech structured its Phase 1 IND in CTD format. By NDA stage, 80% of the Module 2 summaries were already in place. The NDA was submitted four months ahead of internal timelines and received only minor FDA information requests, avoiding major review delays [8].

Startup Tips

• Map all study reports and summaries to CTD modules from the first IND.
• Keep a living Module 2 updated after each study.
• Align clinical pharmacology (2.7.2) with your M&S plan early.
• Maintain CMC documents (Module 3) in CTD-ready format from first GMP batch.

Key Takeaways

• Early CTD alignment isn’t just tidy—it’s strategic.
• Documented cases show 3–6 months saved in NDA/MAA prep.
• The leaner the team, the greater the benefit.

Next in the Series

Coming soon: IND Essentials – Avoiding Startup Pitfalls

References

1. ICH. M4: Common Technical Document (CTD) — Organisation of Modules 2–5. Guidance adopted by EU, Japan, USA.
2. FDA. M4: Organization of the Common Technical Document for the Registration of Pharmaceuticals for Human Use — Guidance for Industry.
3. 21 CFR 312.23 — IND content and format. U.S. Code of Federal Regulations specifying required IND components.
4. FDA. Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs… (Guidance for Industry).
5. FDA. Electronic Common Technical Document (eCTD) — eCTD is the standard format for submissions to CDER/CBER; electronic submission requirements apply to certain INDs, NDAs, BLAs, ANDAs, and master files.
6. FDA. eCTD Technical Conformance Guide — Implements section 745A(a) electronic submission requirements and details scope (including certain INDs).
7. EMA. Guideline on requirements for quality documentation concerning IMPs for clinical trials — IMPD quality part follows CTD Module 3 structure.
8. (Industry anecdote) DIA conference session reports have described time savings when sponsors structure IND content in CTD/eCTD from the outset; however, peer-reviewed, quantified evidence is limited. Treat “3–6 months” as program-dependent and not universally guaranteed.